Diabetic Gastroparesis Candidate Fails in Phase 3 July 26, 2016 EVK-001 failed to meet endpoint in clinical trial. Read More
Topical Ointment Hits Goal in Phase 3 Trials July 25, 2016 Crisaborole achieves endpoint for all age groups. Read More
Zafgen’s Beloranib No Longer in Development July 21, 2016 The company abandoned development due to “obstacles, costs and development timelines.” Read More
Clinical Trial Companies Argue Deaths Not Linked to Trials July 21, 2016 Ziopharm Oncology is reporting that a patient died following intracranial hemorrhaging. Read More
AZ’s Tagrisso Soars in Phase 3 July 20, 2016 The candidate reached its primary endpoint of superior progression-free survival. Read More
Roche’s Blood Cancer Candidate Fails in Phase 3 July 20, 2016 Gazyva floundered in a Phase 3 trial against Rituxan. Read More
Pfizer Nabs Extended Indication for Prevnar 13 July 20, 2016 Prevnar 13 is now indicated for adults between the ages of 18 and 49. Read More
Loxo Oncology Secures Breakthrough Designation July 20, 2016 The company’s tropomyosin receptor kinase inhibitor candidate LOXO-101 scored the designation. Read More
FDA Removes Hold on Juno Therapeutics’ Cancer Trial July 19, 2016 The agency lifted its clinical hold on the company’s research after Juno pledged to alter its protocols. Read More
Sucampo Terminates Development of Cobiprostone July 18, 2016 The company pulled the plug after the candidate failed to show clinical benefit in an ongoing oral mucositis study. Read More
Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study July 18, 2016 The candidate reached all of its co-primary endpoints. Read More
Pfizer’s Sutent Meets Primary Endpoint in Pivotal Trial July 18, 2016 The candidate met its primary endpoint of prolonging disease-free survival. Read More